Literature DB >> 10453718

Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice.

V Knight1, N V Koshkina, J C Waldrep, B C Giovanella, B E Gilbert.   

Abstract

PURPOSE: To test the anticancer properties of the water-insoluble derivative of camptothecin, 9-nitrocamptothecin (9-NC) against human breast, colon and lung cancer xenografts in nude mice when administered in liposome aerosol.
METHODS: The drug was formulated with dilauroylphosphatidylcholine and nebulized in a particle size of 1.6 microm +/- 2.0 mass median diameter to deliver doses of usually less than 200 microg/kg daily, 5 days per week. 9-NC liposome aerosols were generated with a Aerotech II nebulizer (CIS-USA) flowing at 101/min from a compressed air source and delivered to mice in sealed plastic cages or in a nose-only exposure chamber.
RESULTS: Tumor growth was greatly reduced or tumors were undetectable after several weeks of treatment. Colon tumor was least responsive. 9-NC was better than the parent compound, camptothecin, also water-insoluble, tested by aerosol in a similar liposomal preparation. Equivalent doses of 9-NC liposome preparations administered by mouth were substantially without effect while there was some effect, but limited, of the liposome preparation given intramuscularly.
CONCLUSIONS: 9-NC liposome aerosol was strikingly effective in the treatment of three human cancer xenografts growing subcutaneously over the thorax in nude mice at doses much smaller than those traditionally used in mice administered by other routes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10453718     DOI: 10.1007/s002800050965

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.

Authors:  V Knight; N Koshkina; C Waldrep; B C Giovanella; E Kleinerman; B Gilbert
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

Review 2.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 3.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

4.  A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

Authors:  John F Deeken; Rebecca Slack; Glen J Weiss; Ramesh K Ramanathan; Michael J Pishvaian; Jimmy Hwang; Karen Lewandowski; Deepa Subramaniam; Aiwu Ruth He; Ion Cotarla; Aquilur Rahman; John L Marshall
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-30       Impact factor: 3.333

5.  Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.

Authors:  Suniket V Fulzele; Abhijit Chatterjee; Madhu Sudhan Shaik; Tanise Jackson; Mandip Singh
Journal:  Pharm Res       Date:  2006-08-11       Impact factor: 4.200

6.  MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.

Authors:  Brian E Gilbert; Matthew T McLeay
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

7.  Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model.

Authors:  Xian-Ping Liu; Sheng-Tao Zhou; Xing-Yi Li; Xian-Cheng Chen; Xia Zhao; Zhi-Yong Qian; Li-Na Zhou; Zhi-Yong Li; Yu-Mei Wang; Qian Zhong; Tao Yi; Zheng-Yu Li; Xiang He; Yu-Quan Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

8.  Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization.

Authors:  Agnès Maillet; Nicolas Congy-Jolivet; Sandrine Le Guellec; Laurent Vecellio; Sophie Hamard; Yves Courty; Anthony Courtois; Francis Gauthier; Patrice Diot; Gilles Thibault; Etienne Lemarié; Nathalie Heuzé-Vourc'h
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

9.  Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis.

Authors:  Jong K Woo; Dong Soon Choi; Hai T Tran; Brian E Gilbert; Waun Ki Hong; Ho-Young Lee
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

Review 10.  Improved biochemical strategies for targeted delivery of taxoids.

Authors:  Thota Ganesh
Journal:  Bioorg Med Chem       Date:  2007-03-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.